|
Market Report
|
Neuropathic Pain - UCB's Vimpat set to compete with major players
The neuropathic pain market is forecast to almost triple to over $6.3 billion by the end of the forecast period in 2017. The growth in the market is spurred on by the uptake of Pfizer's Lyrica (pregabalin), forecast to reach almost $3 billion in sales by 2017. Vimpat is the most promising pipeline drug, forecast to take some $480m by 2017.
|
|
Read more...
|
|
|
Market Report
|
Non-hormonal Treatments for Menopausal Symptoms - Market open to takers as tepid pipeline fails to meet demand
The treatment of menopausal symptoms is a common clinical challenge, with vasomotor symptoms affecting an estimated 75% of women aged over 50 years. Hormone replacement therapy (HRT) has formed the mainstay of treatment for almost 60 years and is highly efficacious. However, concerns surrounding the safety of HRT have led to an increase in demand for non-hormonal alternatives.
|
|
Read more...
|
|
|
Market Report
|
Rx-to-OTC Strategies: Maximizing the Commercial Potential of an Rx-to-OTC Switch
With the growing cost of developing novel drugs, combined with the fact that fewer such drugs are gaining regulatory approval, the use of lifecycle management is playing an ever-more important role in the increasingly cost-conscious pharma industry. Rx-to-OTC switching is one such strategy employed to either enhance existing franchise revenues or protect branded revenues from generic competition.
|
|
Read more...
|
|
|
Market Report
|
Asthma - Over-prescribing is common in intermittent and mild forms of asthma
Asthma is managed using a step-wise approach, with bronchodilators to relieve symptoms of airflow limitation and controller medications to target underlying inflammation. Datamonitor's research shows that almost all patients (even those with mild intermittent asthma) receive some type of controller medication as their baseline treatment, which is in line with international management guidelines.
|
|
Read more...
|
|
|
Market Report
|
Vaccines for Adults and the Elderly - New blockbuster opportunities ahead
Vaccines have re-emerged as successful revenue generators for Big Pharma, with adults and the elderly now increasingly coming into focus as the next big opportunity in this sector. An aging population, rising disease awareness and new technologies to overcome the scientific hurdles linked to the weakened immune response in the elderly are all contributing factors.
|
|
Read more...
|
|
|
Market Report
|
Fibromyalgia - Approvals legitimize condition and expose underserved patient population
With a considerable patient potential and large medical unmet need, the untapped fibromyalgia market represents a lucrative opportunity for pharmaceutical companies. Estimated to total around $650m in 2007 in the seven major markets, Datamonitor forecasts the market to grow to over $2.4 billion in 2017.
|
|
Read more...
|
|
|
Market Report
|
Novel Therapeutic Approaches in Cardiovascular Medicine - Lack of market prospects for biologics expose an opportunity for cell and gene therapies
At the forefront of novel technologies; momentum is steadily building for the development of stem cell products to address cardiovascular disease. The most active areas are those with high clinical unmet need heart failure, cardiomyopathy and ishemic heart disease.
|
|
Read more...
|
|
|
Market Report
|
Diagnostics in Neurology - Predictive biomarkers expand drug revenues
As advances in omics technologies enable the development of high value molecular diagnostics, neurological conditions represent an attractive target for diagnostic companies. In this report, Datamonitor identifies the diseases in which early detection with a biomarker could significantly benefit the patient, gain payer approval, and ultimately expand the pharmaceutical market.
|
|
Read more...
|
|
|
Market Report
|
Optimizing Brand Lifecycle Management: Winning Strategies to Maximize Revenue in the Face of Growing Generic Competition
As competitive pressures from the entry of generics post-patent expiry and new brands are growing, product lifecycles are evolving for the worst. Effective lifecycle management is becoming a must for Pharma looking to maximize their return on investment, regardless of which stage of the lifecycle a drugs is in. However such strategies are becoming most prominent immediately before patent expiry.
|
|
Read more...
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
|
| Results 10 - 18 of 238 |
Farmavita.Net Journal 
